Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific
OXLUMO® (lumasiran) is now listed on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with primary hyperoxaluria type 1(PH1) [1]
Health Canada Approves BylvayTM (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
AMVUTTRA® (vutrisiran) is now listed on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy [1]
Medison Pharma and Immunocore Announce ANVISA Approval of KIMMTRAK® (tebentafuspe) for the Treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in Brazil[1]
PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
PBS listing for Australians with unresectable or metastatic uveal melanoma
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Sarah Otten Joins Medison Pharma as VP, GM Americas Region
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients
Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand
Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix[®] (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
Victor Papamoniodis Joins Medison Pharma as VP International Markets
Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel
Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
Moderna and Medison Pharma partner to commercialize Moderna’s COVID-19 vaccine across Central Eastern Europe and Israel
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT
BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A
Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
Linkedin
© Copyright 2021 © Medison Pharma. All Rights Reserved.
